CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 20 enrolled
Drug / intervention
Lanadelumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05460325
NCT05460325Phase 3Completed
CompareCT.gov

A Multi-center, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Lanadelumab (SHP643) in Chinese Subjects With Hereditary Angioedema

Takeda·interventional·Posted Jul 15, 2022·Updated Dec 13, 2024

In Brief

A Phase 3 clinical trial evaluating Lanadelumab for Hereditary Angioedema (HAE). Completed, enrolled 20 participants across 4 sites.

Detailed Summary

The main aim of this study is to evaluate the safety of lanadelumab in Chinese participants with HAE. Participants will be treated with lanadelumab for 26 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHereditary Angioedema (HAE)
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedJul 15, 2022
Enrollment StartJun 22, 2022
Primary CompletionNov 28, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.0 years ago

Interventions

Lanadelumabdrug

Lanadelumab subcutaneous injection